Current Report Filing (8-k)
January 06 2021 - 07:26AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
January 6, 2021 (January 5, 2021)
PLURISTEM THERAPEUTICS INC.
(Exact Name of Registrant as Specified in Its
Charter)
Nevada
|
|
001-31392
|
|
98-0351734
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
MATAM Advanced Technology Park
|
|
|
Building No. 5
|
|
|
Haifa, Israel
|
|
3508409
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
011 972 74 710 7171
(Registrant’s telephone number, including
area code)
Not applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.00001 per share
|
|
PSTI
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
|
On January 5, 2021, Pluristem Therapeutics
Inc., or the Company, increased the size of its Board of Directors, or the Board, by two and appointed Maital Shemesh-Rasmussen
and Rami Levy to serve as directors to fill the resulting vacancies, effective immediately. Neither Ms. Shemesh-Rasmussen nor Mr.
Levy were appointed to serve on any Board committees.
Ms. Shemesh-Rasmussen, age 51, served as the
Global Head of Marketing at Roche Diagnostics Information Solutions between 2018 and 2020. Between 2016 and 2018, she worked at
Fitango Health, Inc. where she focused on marketing and business development. Between 2013 and 2016, she led Product Marketing
at the Oracle Health Sciences Global Business Unit, as well as Marketing and Business Development in the Oracle Digital Health
Innovation Unit. Prior to these positions, Ms. Shemesh-Rasmussen served as Vice President at JPMorgan Chase Bank from 2002 until
2007. Ms. Shemesh-Rasmussen holds a BA in Behavioral Sciences from Ben Gurion University.
Mr. Levy, age 62, is the Founder and President
of Catalyst Group International, LLC where, since 2009, he has provided consulting services relating to strategic planning to notable
clients in the private and public sectors. From 2004 to 2006, he served as Senior Deputy General and Head of Marketing Administration
at Israel's Ministry of Tourism. He holds an MA with Honors in Political Science from The Hebrew University of Jerusalem.
As remuneration for their service as directors,
each of Ms. Shemesh-Rasmussen and Mr. Levy will receive the same fees as the Company’s other non-executive directors, as
described in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2020. Except as otherwise set forth
herein, there is no arrangement or understanding between Ms. Shemesh-Rasmussen or Mr. Levy and any other person pursuant to which
they were elected as directors, and there are no transactions in which Ms. Shemesh-Rasmussen or Mr. Levy has an interest requiring
disclosure under Item 404(a) of Regulation S-K. In connection with their respective appointments, the Company expects to enter
into its standard indemnification agreements with Ms. Shemesh-Rasmussen and Mr. Levy, on substantially the same terms as the indemnification
agreements previously entered into between the Company and each of its directors and executive officers.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
PLURISTEM THERAPEUTICS INC.
|
|
|
|
|
By:
|
/s/ Chen Franco-Yehuda
|
|
Name:
|
Chen Franco-Yehuda
|
|
Title:
|
Chief Financial Officer
|
Date: January 6, 2021
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Pluristem Therapeutics (NASDAQ:PSTI)
Historical Stock Chart
From Mar 2023 to Mar 2024